Debate Series - Estro-events.org
Debate Series - Estro-events.org
Debate Series - Estro-events.org
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
posTErs<br />
Posters<br />
Page 422 PROgRammE & ExhibiTiOn guidE • WCB 2012<br />
abS. numbER<br />
> PSA response to tri-modality predicts biochemical progression free<br />
survival in localized prostate cancer<br />
M. Aoki (Japan), K. Miki, Y. Yamamoto, M. Kido, S. Takaki,<br />
M. Kobayashi, C. Kanehira, S. Egawa PO-163<br />
> Seed migration in prostate brachytherapy depends on experience<br />
and technique<br />
G. Delouya (Canada), D. Taussky, C. Moumdjian, R. Larouche,<br />
D. Béliveau-Nadeau, C. Boudreau, Y. Hervieux, D. Donath PO-164<br />
> Focal therapy for prostate cancer recurrences: feasibility,<br />
toxicity and quality of life of I-125 focal salvage<br />
M. van Vulpen (The Netherlands), M. Peters, M.R. Moman,<br />
U.A. van der Heide, J.J. Battermann, S. Franken, M. van Deursen,<br />
M.A. Moerland PO-165<br />
> Permanent prostate brachytherapy in Japanese patients with<br />
small prostate glands<br />
K. Kobayashi (Japan), K. Okihara, K. Kamoi, T. Iwata, T. Tsubokura,<br />
N. Aibe, N. Kodani, T. Miki, H. Yamazaki PO-166<br />
> Impact of embedded seeds on dose distributions in X-ray radiotherapy:<br />
a phantom study with Monte Carlo calculation<br />
K. Shiraishi (Japan), A. Sakumi, A. Haga, T. Onoe, K. Yamamoto,<br />
K. Okuma, K. Yoda, K. Nakagawa PO-167<br />
> Validity of intraoperative interactive planning technique based<br />
on anatomic distribution of prostate cancer<br />
O. Keisei (Japan), N. Kohno, Y. Okinaka, Y. Okada, K. Murata PO-168<br />
> Brachytherapy for young prostate cancer patients.<br />
What is different from elder patients?<br />
Y. Yagi (Japan), A. Ashikari, R. Namitome, T. Nishiyama, K. Toya,<br />
A. Yorozu, S. Saito PO-169<br />
Posters<br />
abS. numbER<br />
> Exclusive Iodine 125 prostate brachytherapy.<br />
Experience of Institut Bergonié<br />
L. Thomas (France), A. Chemin, S. Belhomme, O. Lasbareilles,<br />
J. Mendiboure, N. Houédé, E. Descat, D. Monnin, P. Richaud PO-170<br />
> DNA ploidy based on archived biopsy material may correlate<br />
with PSA recurrence after prostate brachytherapy<br />
M. Keyes (Canada), M. MacAulay, M. Hayes, J. Korbelik, D. Garner,<br />
J.W. Morris, B. Palcic PO-171<br />
> Current risk classification for prostate cancer does not accurately<br />
predict survival after I-125 brachytherapy<br />
L. Kerkmeijer (The Netherlands), E. Monninkhof, M. Van Vulpen PO-172<br />
> Iodine-125 (I-125) low dose rate (LDR) brachytherapy for higher<br />
risk (HR) prostate cancer<br />
R. Conroy (United Kingdom), J. Malik, P. Mandell, R. Swindell,<br />
P. Hoskin, D. Bottomley, J. Logue, J. Wylie PO-173<br />
> HDR brachytherapy boost for localised prostate cancer:<br />
the first 150 patients from the Sydney Cancer Centre.<br />
D. Whalley (Australia), N. Patanjali, M. Jackson, G. Perez,<br />
M. Whittaker, M. Chatfield, G. Hruby PO-174<br />
> Catheter position control in high dose rate brachytherapy of<br />
prostate cancer<br />
P. Marolt (Slovenia), R. Hudej, A. Bernik PO-175<br />
> Efficacy, toxicity and dosimetric aspects of HDR brachytherapy in<br />
prostate cancer patients: 5 years experience<br />
T.M. Filipowski (Poland), A. Szmigiel-Trzcinska, J. Topczewska-Bruns,<br />
B. Pancewicz-Janczuk, W. Nowik PO-176<br />
> HistoScanning based dose escalation for prostate cancer as<br />
microboost using brachytherapy– a phase II-trial<br />
S. Lettmaier (Germany), S. Kreppner, M. Lotter, R. Fietkau, V. Strnad PO-177<br />
WCB 2012 • PROgRammE & ExhibiTiOn guidE Page 423<br />
posTErs<br />
WCB
Change language